Envoy Medical
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional ...
Latest News
20 days ago · newsfilecorp.com
Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5thFinancial Results to Be Released Before Market Open White Bear Lake, Minnesota--(Newsfile Corp. - October 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has updated the time of its conference call to discuss financial results for the third quarter ended September 30, 2026. The conference call will now be held at 8:00 A.M.
21 days ago · newsfilecorp.com
Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5thManagement Will Host a Conference Call at 4:30 P.M. ET on the Same Day White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it will report its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026.
26 days ago · newsfilecorp.com
Envoy Medical Announces Reverse Stock SplitWhite Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the "Reverse Split").
28 days ago · newsfilecorp.com
Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device DesignCompany Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear Implant Remains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA Module by End of Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has surpassed the six-month follow-up visit milestone for the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This milestone signifies the halfway point in the trial's final stage of data collection as each participant is followed for a total of 12 months.
1 month ago · newsfilecorp.com
Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear ImplantSecond of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced the submission of the second module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Acclaim® cochlear implant, which has received FDA Breakthrough Device Designation. The second module, which included primarily engineering information, follows the Company's submission of the first module on June 30, 2026.
2 months ago · newsfilecorp.com
Envoy Medical Announces New Patents, Further Expanding Global Patent PortfolioCanadian and Hong Kong Patents Continue to Strengthen Intellectual Property Protection Across Envoy Medical's Fully Implanted Hearing Platform White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications.
3 months ago · newsfilecorp.com
Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16thWhite Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical ® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.
3 months ago · zacks.com
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue EstimatesEnvoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.32 per share a year ago.
3 months ago · newsfilecorp.com
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical MilestonesSubmitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives. "The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market," said Brent Lucas, Chief Executive Officer of Envoy Medical.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove COCH